Wedbush Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN), but has lowered the price target from $48 to $45.
July 11, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush maintains an Outperform rating on Viridian Therapeutics, but has lowered the price target from $48 to $45.
The news is directly about Viridian Therapeutics. While the Outperform rating is maintained, which is positive, the lowering of the price target might have a neutral to slightly negative impact on the stock in the short term as it indicates a lower future valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100